Diagnosis of Drug Resistance of M. tuberculosis in the Regions of the Siberian Federal District

Q4 Medicine

Tuberculosis and Lung Diseases Pub Date : 2024-07-04 DOI:10.58838/2075-1230-2024-102-3-48-57

N. V. Stavitskaya, I. G. Felker, E. K. Nemkova

{"title":"Diagnosis of Drug Resistance of M. tuberculosis in the Regions of the Siberian Federal District","authors":"N. V. Stavitskaya, I. G. Felker, E. K. Nemkova","doi":"10.58838/2075-1230-2024-102-3-48-57","DOIUrl":null,"url":null,"abstract":"The objective: to assess possibilities for timely diagnosis of drug resistance of M. tuberculosis in the regions of the Siberian Federal District (SFD) with a high burden of drug resistant tuberculosis.Subjects and Methods. The retrospective analysis included federal and sectorial statistical reporting data (Form no. 33, Form no. 8, Form no. 30, Form no. 7-TB, Form no. 8-TB), forms of non-recurrent statistical surveillance VR-5MLU, Form no. 68, data from Visit Reports by specialists of Novosibirsk Tuberculosis Research Institute by the Russian Ministry of Health for 2021 – 9 months of 2023.Results. All laboratories of TB units in the regions of the Siberian Federal District are equipped with equipment for rapid molecular genetic diagnosis of M. tuberculosis, however, the majority of laboratories have no possibility to conduct rapid molecular genetic DST to fluoroquinolones. In a number of regions no DST to levofloxacin and moxifloxacin is performed. Susceptibility testing to linezolid and bedaquiline is conducted extremely rarely. Susceptibility testing to delamanid is performed in single cases and only in one region. To achieve treatment effectiveness rates defined in Edict no. 19 by Russian Ministry of Health dated February 07, 2023, it is necessary to equip TB units with modern equipment for rapid DST, organize an uninterrupted supply of consumables, as well as train laboratory personnel in the shortest possible time.","PeriodicalId":37828,"journal":{"name":"Tuberculosis and Lung Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Lung Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58838/2075-1230-2024-102-3-48-57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The objective: to assess possibilities for timely diagnosis of drug resistance of M. tuberculosis in the regions of the Siberian Federal District (SFD) with a high burden of drug resistant tuberculosis.Subjects and Methods. The retrospective analysis included federal and sectorial statistical reporting data (Form no. 33, Form no. 8, Form no. 30, Form no. 7-TB, Form no. 8-TB), forms of non-recurrent statistical surveillance VR-5MLU, Form no. 68, data from Visit Reports by specialists of Novosibirsk Tuberculosis Research Institute by the Russian Ministry of Health for 2021 – 9 months of 2023.Results. All laboratories of TB units in the regions of the Siberian Federal District are equipped with equipment for rapid molecular genetic diagnosis of M. tuberculosis, however, the majority of laboratories have no possibility to conduct rapid molecular genetic DST to fluoroquinolones. In a number of regions no DST to levofloxacin and moxifloxacin is performed. Susceptibility testing to linezolid and bedaquiline is conducted extremely rarely. Susceptibility testing to delamanid is performed in single cases and only in one region. To achieve treatment effectiveness rates defined in Edict no. 19 by Russian Ministry of Health dated February 07, 2023, it is necessary to equip TB units with modern equipment for rapid DST, organize an uninterrupted supply of consumables, as well as train laboratory personnel in the shortest possible time.

查看原文本刊更多论文

西伯利亚联邦区结核杆菌耐药性诊断

目的：评估在耐药性结核病高发的西伯利亚联邦区（SFD）及时诊断结核杆菌耐药性的可能性。回顾性分析包括联邦和部门统计报告数据（第33号表、第8号表、第30号表、第7-结核病表、第8-结核病表）、非经常性统计监测表VR-5MLU、第68号表、俄罗斯卫生部新西伯利亚结核病研究所专家2021-2023年9个月的访问报告数据。西伯利亚联邦区各州结核病防治单位的所有实验室都配备了结核杆菌快速分子遗传学诊断设备，但大多数实验室无法对氟喹诺酮类药物进行快速分子遗传学 DST 检测。一些地区没有对左氧氟沙星和莫西沙星进行 DST 检测。对利奈唑胺和贝达喹啉的药敏试验极少进行。对地拉那米德的药敏试验仅在一个地区的单个病例中进行。为了达到俄罗斯卫生部 2023 年 2 月 7 日第 19 号敕令规定的治疗有效率，有必要为结核病防治单位配备用于快速 DST 检测的现代化设备，组织不间断的耗材供应，并在尽可能短的时间内对实验室人员进行培训。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tuberculosis and Lung Diseases Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： The Journal is aimed for professional development of researchers, doctors, teachers of medical universities and training institutions. The Journal focuses on the presentation of results of research, case studies, issues of differential diagnostics and treatment in the phthisiologist’s practice, national programs on tuberculosis control in the Russian Federation, WHO strategies, discussion of prevention issues to stop transmission of TB/HIVco-infection, and extrapulmonary tuberculosis.